enGene Inc., a biotechnology company developing a robust platform to deliver genes to mucosal cells lining the gut, today announced that data from preclinical studies demonstrated successful expression of programmed death - ligand 1 (PD-L1) protein in the gut showing therapeutic efficacies in mouse models of inflammatory bowel disease (IBD) and graft - versus - host disease (GvHD). This study has been selected for presentation at the DD W2017 conference, the world’s most prestigious meeting of GI professionals, attracting 15,000 physicians, researchers and academics.